Biotechnology PTC Therapeutics Inks Licensing Pact With Novartis Worth Up To ~$3 Billion For Huntington’s Program – PTC Therapeutics (NASDAQ:PTCT), Novartis (NYSE:NVS) Read more
Biotechnology PTC Therapeutics To Withdraw Its Conditionally Approved Rare Muscle Disorder Disorder Drug In Europe – PTC Therapeutics (NASDAQ:PTCT) Read more
